SpringWorks Therapeutics (SWTX) Competitors

Genmab A/S (NASDAQ:GMAB) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, community ranking, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Which has preferable valuation & earnings, GMAB or SWTX?

Genmab A/S has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	4.22	$1.14B	$1.76	11.66
SpringWorks Therapeutics	$219.67M	15.85	-$325.10M	-$3.41	-13.55

Which has more risk & volatility, GMAB or SWTX?

Genmab A/S has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

Is GMAB or SWTX more profitable?

Genmab A/S has a net margin of 36.30% compared to SpringWorks Therapeutics' net margin of -134.73%. Genmab A/S's return on equity of 16.78% beat SpringWorks Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	36.30%	16.78%	13.79%
SpringWorks Therapeutics	-134.73%	-46.74%	-41.12%

Does the media favor GMAB or SWTX?

In the previous week, Genmab A/S had 9 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 19 mentions for Genmab A/S and 10 mentions for SpringWorks Therapeutics. SpringWorks Therapeutics' average media sentiment score of 1.64 beat Genmab A/S's score of 0.78 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SpringWorks Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts recommend GMAB or SWTX?

Genmab A/S presently has a consensus target price of $39.17, indicating a potential upside of 90.87%. SpringWorks Therapeutics has a consensus target price of $52.57, indicating a potential upside of 13.77%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than SpringWorks Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
SpringWorks Therapeutics	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.13

Does the MarketBeat Community favor GMAB or SWTX?

Genmab A/S received 61 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. However, 67.95% of users gave SpringWorks Therapeutics an outperform vote while only 63.02% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 167 63.02%	Underperform Votes 98 36.98%
SpringWorks Therapeutics	Outperform Votes 106 67.95%	Underperform Votes 50 32.05%

Do institutionals and insiders hold more shares of GMAB or SWTX?

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 7.8% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Genmab A/S beats SpringWorks Therapeutics on 15 of the 19 factors compared between the two stocks.